|
Aug 12
|
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72
|
|
Aug 12
|
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2
|
|
Aug 11
|
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
|
|
Aug 8
|
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
|
|
Aug 7
|
Halozyme Therapeutics Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 6
|
Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says
|
|
Aug 6
|
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...
|
|
Aug 5
|
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
|
|
Aug 5
|
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
|
|
Aug 5
|
Halozyme Therapeutics: Q2 Earnings Snapshot
|
|
Aug 5
|
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
|
|
Jul 29
|
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
|
|
Jul 28
|
Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT
|
|
Jul 23
|
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
|
|
Jul 23
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jul 22
|
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
|
|
Jul 22
|
Halozyme to Report Second Quarter 2025 Financial and Operating Results
|
|
Jun 30
|
Halozyme Therapeutics Added to Russell 1000® Index
|
|
Jun 17
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jun 16
|
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
|